SIONNA THERAPEUTICS, INC. (SION) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$32.47M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$29.60M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$23.80M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$21.91M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$32.47M | (m) | (m) | (m) | $0.00* | -$22.22M* | (m) | $21.86M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$29.60M | (m) | (m) | (m) | $0.00 | -$21.84M | (m) | $18.96M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$23.80M | (m) | (m) | (m) | $87.00K* | -$15.23M* | (m) | $16.04M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$21.91M | (m) | (m) | (m) | $0.00* | -$18.15M* | (m) | $15.38M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$19.66M | (m) | (m) | (m) | $86.00K | -$16.29M | (m) | $13.67M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$27.98M | (m) | (m) | (m) | $0.00* | -$17.69M* | (m) | $24.58M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$11.29M | (m) | (m) | (m) | $0.00* | -$10.14M* | (m) | $8.23M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$13.15M | (m) | (m) | (m) | $0.00 | -$13.18M | (m) | $10.22M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$88.98M | (m) | (m) | (m) | $377.00K | -$66.30M | (m) | $60.26M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$70.56M | (m) | (m) | (m) | $27.00K | -$52.79M | (m) | $57.29M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |